IL149495A0 - Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy - Google Patents

Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy

Info

Publication number
IL149495A0
IL149495A0 IL14949500A IL14949500A IL149495A0 IL 149495 A0 IL149495 A0 IL 149495A0 IL 14949500 A IL14949500 A IL 14949500A IL 14949500 A IL14949500 A IL 14949500A IL 149495 A0 IL149495 A0 IL 149495A0
Authority
IL
Israel
Prior art keywords
therapy
receptor antagonist
pharmaceutical formulations
thrombotic agent
thrombotic
Prior art date
Application number
IL14949500A
Other languages
English (en)
Original Assignee
Astrazeneca Ab Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab Astrazeneca Ab filed Critical Astrazeneca Ab Astrazeneca Ab
Publication of IL149495A0 publication Critical patent/IL149495A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14949500A 1999-12-01 2000-11-29 Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy IL149495A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904377A SE9904377D0 (sv) 1999-12-01 1999-12-01 Pharmaceutical combinations
PCT/SE2000/002378 WO2001039781A1 (fr) 1999-12-01 2000-11-29 Combinaisons pharmaceutiques

Publications (1)

Publication Number Publication Date
IL149495A0 true IL149495A0 (en) 2004-03-28

Family

ID=20417947

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14949500A IL149495A0 (en) 1999-12-01 2000-11-29 Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy

Country Status (33)

Country Link
US (2) US20030032618A1 (fr)
EP (2) EP1237559B1 (fr)
JP (1) JP2003515565A (fr)
KR (1) KR100785953B1 (fr)
CN (1) CN1402639A (fr)
AR (1) AR033658A1 (fr)
AT (1) ATE332698T1 (fr)
AU (1) AU781691B2 (fr)
BR (1) BR0016043A (fr)
CA (1) CA2391161C (fr)
CO (1) CO5271717A1 (fr)
CY (1) CY1105211T1 (fr)
CZ (1) CZ300925B6 (fr)
DE (1) DE60029340T2 (fr)
DK (1) DK1237559T3 (fr)
EE (1) EE05127B1 (fr)
ES (1) ES2267591T3 (fr)
HK (1) HK1047893A1 (fr)
HU (1) HU230890B1 (fr)
IL (1) IL149495A0 (fr)
IS (1) IS2841B (fr)
MX (1) MXPA02004871A (fr)
MY (1) MY128896A (fr)
NO (1) NO331215B1 (fr)
NZ (2) NZ518904A (fr)
PT (1) PT1237559E (fr)
RU (1) RU2242232C2 (fr)
SE (1) SE9904377D0 (fr)
SI (1) SI1237559T1 (fr)
SK (1) SK288707B6 (fr)
TW (1) TWI251491B (fr)
WO (1) WO2001039781A1 (fr)
ZA (1) ZA200203707B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
EP1604669A1 (fr) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation d'analogues de l'ATP pour le traitement de maladies cardiovasculaires
CA2618187C (fr) * 2005-09-21 2011-06-21 Chong Kun Dang Pharmaceutical Corp. Nouveau complexe de resinate de s-clopidogrel et procede pour le produire
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (fr) 2008-05-13 2009-11-19 The Medicines Company Conservation de l'inhibition de plaquettes durant une thérapie anti-plaquettes
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
CA2778880C (fr) * 2009-11-11 2018-02-13 The Medicines Company Procedes de traitement ou de prevention de thrombose de stent
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2672975B1 (fr) 2011-02-09 2016-04-20 The Medicines Company Méthodes de traitement de l'hypertension pulmonaire
ES2904256T3 (es) 2013-03-09 2022-04-04 Chiesi Farm Spa Métodos para tratar, reducir la incidencia de y/o prevenir eventos isquémicos
BR112019022676A2 (pt) 2017-06-23 2020-05-19 Chiesi Farm Spa método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826448D0 (en) * 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
PL297372A1 (en) * 1991-04-06 1993-09-06 Fisons Plc Atp analogs
CA2155673C (fr) * 1993-02-10 2004-08-17 Anthony Howard Ingall Analogues d'atp n-alkyles-2-substitues
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
ATE217010T1 (de) * 1995-07-11 2002-05-15 Astrazeneca Ab Inhibitoren der plättchenaggregation
DE69926750T2 (de) * 1998-06-17 2006-06-29 Bristol-Myers Squibb Co. Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
WO2004031143A2 (fr) * 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Combinaison d'un inhibiteur de facteur x$g(a) et de clopidogrel
EP1652532A1 (fr) * 2003-07-16 2006-05-03 Kyowa Hakko Kogyo Co., Ltd. Composition medicinale

Also Published As

Publication number Publication date
ATE332698T1 (de) 2006-08-15
WO2001039781A1 (fr) 2001-06-07
ZA200203707B (en) 2003-10-29
MY128896A (en) 2007-02-28
NZ530058A (en) 2005-04-29
CA2391161A1 (fr) 2001-06-07
CA2391161C (fr) 2010-10-05
DE60029340T2 (de) 2007-07-19
ES2267591T3 (es) 2007-03-16
NZ518904A (en) 2004-02-27
JP2003515565A (ja) 2003-05-07
EP1719526A2 (fr) 2006-11-08
CZ300925B6 (cs) 2009-09-09
US20060270607A1 (en) 2006-11-30
CO5271717A1 (es) 2003-04-30
KR20020069201A (ko) 2002-08-29
NO331215B1 (no) 2011-11-07
SE9904377D0 (sv) 1999-12-01
US20030032618A1 (en) 2003-02-13
EP1237559A1 (fr) 2002-09-11
NO20022606D0 (no) 2002-05-31
EE200200271A (et) 2003-06-16
AU781691B2 (en) 2005-06-09
RU2242232C2 (ru) 2004-12-20
CN1402639A (zh) 2003-03-12
DE60029340D1 (de) 2006-08-24
HK1047893A1 (en) 2003-03-14
EP1719526A3 (fr) 2007-04-25
AR033658A1 (es) 2004-01-07
PT1237559E (pt) 2006-10-31
TWI251491B (en) 2006-03-21
CZ20021887A3 (cs) 2002-11-13
DK1237559T3 (da) 2006-10-30
HUP0203585A2 (hu) 2003-03-28
EP1237559B1 (fr) 2006-07-12
AU1910901A (en) 2001-06-12
EE05127B1 (et) 2009-02-16
BR0016043A (pt) 2002-07-23
SK288707B6 (sk) 2019-10-02
SI1237559T1 (sl) 2007-02-28
KR100785953B1 (ko) 2007-12-14
RU2002117296A (ru) 2004-01-20
MXPA02004871A (es) 2002-08-30
HU230890B1 (hu) 2018-12-28
SK7502002A3 (en) 2003-02-04
CY1105211T1 (el) 2010-03-03
NO20022606L (no) 2002-07-11
PL355841A1 (en) 2004-05-17
IS6398A (is) 2002-05-27
IS2841B (is) 2013-08-15
HUP0203585A3 (en) 2005-01-28

Similar Documents

Publication Publication Date Title
IL149495A0 (en) Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy
HUP0203638A3 (en) Betha2-adrenergic receptor agonists and pharmaceutical compositions containing them and their use
HUP0200548A2 (hu) Gyógyszerészeti készítmények és alkalmazásuk
HUP0203588A3 (en) Analgesic pharmaceutical compositions and their use
EG24408A (en) Low dose entecavir formulation and use
MXPA02004770A (es) Composiciones terapeuticas y metodos para su uso.
IL153708A0 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
GB0004167D0 (en) 1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents
AU7002501A (en) Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
IL158780A0 (en) Pharmaceutical combinations comprising a p2t (p2y12) receptor antagonist and another anti-thrombotic agent and their use in the treatment and prevention of thrombosis
IL145715A0 (en) Formulation arrays and use thereof
AU1164601A (en) Therapeutic use and formulation
EP1292309A4 (fr) Utilisation prophylactique et therapeutique d'oltipraz en tant qu'agent anti-fibrotique et anti-cirrhotique dans le foie et composition pharmaceutique contenant de l'oltipraz
PL339848A1 (en) Therapeutic agent against hypephosphataemia
HUP0203627A3 (en) N-guanidinoalkylamides, their preparation, their use, and pharmaceutical compositions comprising them
EP1207812A4 (fr) Dispositif de guidage d'implant et d'administration d'un agent
HK1040196A1 (zh) 低劑量艾替開韋製劑及其應用
HUP0003074A3 (en) Pharmaceutical composition comprising ssri and betha-blocking agent
HUP0301119A3 (en) Biologically active agent and drug
GB9926528D0 (en) Therapeutic use and formulation
IL150237A0 (en) Benzophenone glycopyranosides, preparation and therapeutic use
IL149653A0 (en) 2-arylquinoline derivatives, preparation and therapeutic use thereof
HUP0201875A2 (en) Use of antiprogestagens for preparing pharmaceutical compositions for contraception in combined therapy
GB0023473D0 (en) Therapeutic use and formulation
GB9923431D0 (en) Pharmaceutical compositions and their use